Literature DB >> 16265715

Fibromyalgia syndrome.

Philip J Mease1, Daniel J Clauw, Lesley M Arnold, Don L Goldenberg, James Witter, David A Williams, Lee S Simon, C Vibeke Strand, Candace Bramson, Susan Martin, Timothy M Wright, Bruce Littman, J F Wernicke, R Michael Gendreau, Leslie J Crofford.   

Abstract

The objectives of the first OMERACT Fibromyalgia Syndrome (FM) Workshop were to identify and prioritize symptom domains that should be consistently evaluated in FM clinical trials, and to identify aspects of domains and outcome measures that should be part of a concerted research agenda of FM researchers. Such an effort will help standardize and improve the quality of outcomes research in FM. A principal assumption in this workshop has been that there exists a clinical syndrome, generally known as FM, characterized by chronic widespread pain typically associated with fatigue, sleep disturbance, mood disturbance, and other symptoms and signs, and considered to be related to central neuromodulatory dysregulation. FM can be diagnosed using 1990 American College of Rheumatology criteria. In preparation for the workshop a Delphi exercise involving 23 FM researchers was conducted to establish a preliminary prioritization of domains of inquiry. At the OMERACT meeting, the workshop included presentation of the Delphi results; a review of placebo-controlled trials of FM treatment, with a focus on the outcome measures used and their performance; a panel discussion of the key issues in FM trials, from both an investigator and regulatory agency perspective; and a voting process by the workshop attendees. The results of the workshop were presented in the plenary session on the final day of the meeting. A prioritized list of domains of FM to be investigated was thus developed, key issues and controversies in the field were debated, and consensus on a research agenda on outcome measure development was reached.

Entities:  

Mesh:

Year:  2005        PMID: 16265715

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  53 in total

Review 1.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

2.  QT dispersion and P wave dispersion in patients with fibromyalgia.

Authors:  Servet Yolbaş; Ahmet Yıldırım; Deccane Düzenci; Bülent Karakaya; Mustafa Necati Dağlı; Süleyman Serdar Koca
Journal:  Eur J Rheumatol       Date:  2016-12-01

Review 3.  Fibromyalgia: a rheumatologic diagnosis?

Authors:  Gerhard K M Endresen
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

Review 4.  Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?

Authors:  Philip J Mease; Kristin Seymour
Journal:  Curr Pain Headache Rep       Date:  2008-12

Review 5.  Advances in the assessment of fibromyalgia.

Authors:  David A Williams; Stephen Schilling
Journal:  Rheum Dis Clin North Am       Date:  2009-05       Impact factor: 2.670

6.  Understanding fibromyalgia and its related disorders.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  Musculoskeletal sensitization and sleep: chronic muscle pain fragments sleep of mice without altering its duration.

Authors:  Blair C Sutton; Mark R Opp
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

8.  Sleep fragmentation exacerbates mechanical hypersensitivity and alters subsequent sleep-wake behavior in a mouse model of musculoskeletal sensitization.

Authors:  Blair C Sutton; Mark R Opp
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

9.  Is fibromyalgia a cause of failure in the treatment of a painful shoulder?

Authors:  D Blonna; E Bellato; E Marini; N Barbasetti; L Mattei; F Fissore; C Arrigoni; F Castoldi
Journal:  Musculoskelet Surg       Date:  2013-04-16

10.  Urinary albumin, protein excretion and circadian blood pressure in patients with fibromyalgia.

Authors:  Baris Afsar; Rukuye Burucu
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.